Company ProfilePremium

Hearts and Minds Investments Limited

Company Profile Analysis

Ticker: HM1.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Hearts and Minds Investments Limited - Company showcase

Year Founded & Workforce

2018

4 Employees

Hearts and Minds Investments Limited logo

Hearts and Minds Investments Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Hearts and Minds Investments Limited Overview

Hearts and Minds Investments is a philanthropic listed investment company that offers Australian investors a concentrated, high-conviction portfolio of global equities without charging management or performance fees. Instead, its selected fund managers contribute their best ideas pro bono, and the company donates the equivalent of 1.5% of net tangible assets each year to Australian medical research organisations. Roughly 65% of the portfolio follows the ongoing top picks of a panel of Core Fund Managers (five at 30 June 2026: Caledonia, Magellan Investment Partners, Munro Partners, Prusik and TDM Growth Partners), and about 35% follows the annual stock pitches made at the Sohn Hearts & Minds Investment Leaders Conference, held for up to 12 months. With net assets of about A$774 million, a four-person executive team, an unpaid board, a progressive fully franked dividend policy and A$96.1 million in cumulative medical research donations alongside the conference, HM1 sits at the intersection of active global equities and structured philanthropy.


Company's own description (paraphrased from FY2026 Annual Report)

The Directors' Report describes HM1's principal activity as providing a concentrated investment portfolio of the highest conviction ideas from selected fund managers while also supporting Australian medical research organisations, and states that no change to this activity occurred or is expected. The Chair and Managing Director's letter frames HM1 as born from the investment and philanthropic vision of the Sohn Hearts & Minds Conference, with a "dual mission" of investment performance and social impact. The company's website describes the portfolio as 25–35 carefully chosen securities, actively managed by the Chief Investment Officer under Investment Committee oversight.

Independent characterisation

HM1 is a closed-end, internally administered, externally advised (but not externally managed) global equity vehicle. Its economic engine is the change in market value of roughly 25–30 listed and (minimally) unlisted equities, plus dividends received. It has no operating business, no customers in the conventional sense, no debt and no goodwill. Its "revenue" under Australian Accounting Standards is total investment income — realised and unrealised gains/losses on financial assets and foreign exchange plus dividends — which is inherently volatile and can be negative.

The distinctive feature is its cost structure. A conventional global equity LIC of HM1's size would typically pay a base management fee of roughly 1–1.5% of assets plus performance fees to an external manager. HM1 instead pays nothing to its managers (the company estimates fees forgone at A$12.4 million in FY2026) and directs an approximately equivalent sum (1.5% of average NTA, A$11.5 million expensed in FY2026) to medical research. Shareholders therefore bear an all-in cost similar to a conventional active fund, but the benefit accrues to charitable research rather than to manager profits. Non-donation operating costs (staff, administration, listing) are very low at roughly 0.28% of average equity in FY2026.

Revenue model mix

Component of total investment income (AUD Mn)FY2023FY2024FY2025FY2026
Net realised gains on financial assets (FVTPL)-71.4918.9356.0579.59
Net unrealised gains on financial assets (FVTPL)121.6758.4496.70-6.34
Net realised FX gains2.18-9.30-9.446.00
Net unrealised FX gains-0.148.2813.24-9.82
Dividend income (net of withholding tax)5.357.018.589.88
Interest, sundry and other income0.010.010.350.01
Total investment income57.5883.37165.4879.32

Source: FY2024 and FY2026 Statements of Comprehensive Income. Note: gains on investments made before 12 October 2021 that are classified at fair value through other comprehensive income (FVTOCI) bypass this line and flow through OCI.

Mix characterisation: "Product vs service vs subscription vs licensing" is not applicable. Income is approximately 85–95% capital gains/losses (realised and unrealised, including FX) and 5–15% dividend income in normal years; dividends were 12.5% of total investment income in FY2026 and 5.2% in FY2025.

Value-chain position and "customers"

Capital providers (shareholders): predominantly Australian retail and high-net-worth investors, SMSFs and philanthropic foundations (e.g., Paul Ramsay Foundation holds 4.27 million shares). Shareholders value franking credits — the company's dividend policy is explicitly designed to release franking credits.

Idea suppliers (pro bono): Core Fund Managers and annual Conference Fund Managers.

Beneficiaries: 21 Australian medical research organisations listed in the FY2026 Medical Research Report.

Service providers: Citco (administration), Boardroom (registry and company secretarial), Pitcher Partners (audit), JP Morgan (custody), many on pro bono or discounted terms per the FY2026 Chair's letter.

End-markets

HM1 invests in global listed equities. At 30 June 2026, the portfolio's currency exposure was 68% USD, 15% HKD, 10% EUR, 4% CAD, with the balance in AUD (FY26 AR Note 13). Sector exposure at FY2026 skewed to semiconductors and AI infrastructure (TSMC, Nvidia, ACM Research), consumer/retail, energy/resources (Cameco, SLB, Steel Dynamics), Asian conglomerates/financials (CK Hutchison, Swire Pacific, AIA) and a residual software sleeve (Microsoft, SAP, Monday.com, BlackLine).

Strategy

Stated strategy (themes from FY2026 Annual Report, paraphrased)

  1. Dual mission: deliver investment performance and enduring social impact via medical research funding.

  2. Best-ideas access: expose investors to the highest-conviction ideas of selected managers, several not otherwise accessible to Australian retail investors.

  3. Style diversification: avoid dependence on any single manager's philosophy by blending multiple Core and Conference managers.

  4. Medium-term horizon: target attractive shareholder returns over five years or more.

  5. Full investment: remain fully invested subject to a cash buffer.

  6. Discount narrowing: the Board states it is committed to narrowing the share price discount to NTA.

  7. Progressive fully franked dividends: subject to profit reserves and franking balance; policy (Aug 2025) to add 0.5c per share each half-year.

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus / target
Portfolio management automationH1 2025CEO Jollie's operating-model review implemented a system to automate and improve portfolio managementCompleted; enabled leaner structure
Lean leadership modelMay–Jun 2025Full-time CEO replaced with part-time MDImplemented; KMP cost fell from A$1.09m (FY25) to A$0.49m (FY26)
Progressive dividend policyAug 2025+0.5c per share every six months9.0c (Oct 2025), 9.5c (Apr 2026), 10.0c (Oct 2026) delivered
Offshore Core managerSep 2025Prusik Investment Management added (Asia ex-Japan)Strong first year per FY26 AR
Core manager panel rationalisationFY2025–FY2026Panel reduced from seven (Caledonia, Cooper, Magellan, Munro, Regal, TDM, Tribeca at FY24) to five (Caledonia, Magellan, Munro, Prusik, TDM)Exit dates for Cooper, Regal, Tribeca not disclosed in sources reviewed
Plato red-flag risk screenAnnounced Aug 2026Plato Asset Management sharing (pro bono) a proprietary system scoring stocks on 150+ categories (forensic accounting, governance, remuneration, management behaviour) to exclude problematic stocksBeing integrated; further detail promised in coming months
Conference internationalisation2,026First offshore Sohn Hearts & Minds Conference in Queenstown, NZScheduled 6 Nov 2026
"Hearts & Minds Ampersand" brand/identity2025–26New brand device referenced on websiteNot detailed
10-year anniversary campaignMay 2026Ten years of Hearts & Minds; target of ~A$100m donations in first ten yearsA$96.1m cumulative (HM1 + conference) at FY26

ESG/sustainability commitments

Donation of 1.5% of NTA per annum to medical research (structural, ongoing). No emissions or climate targets disclosed.

Medium-term targets / guidance

No earnings, NTA or return guidance (the Directors state it is not possible or appropriate to predict performance). The only quantified forward commitments are (i) the 0.5c per half-year dividend increment, implying a 10.5c interim in April 2027 if maintained, and (ii) the 1.5% NTA donation rate.

Products & Services

Investor-facing offerings

OfferingDescriptionTarget userLaunchPricing
HM1 ordinary sharesASX-listed exposure to concentrated global equity portfolioRetail, SMSF, HNW, foundationsNov 2018Market price; trades at a discount to NTA (12.7% to post-tax NTA at 30 Jun 2026)
Fully franked dividend streamHalf-yearly since FY2024; progressive +0.5c/half policyIncome/franking-sensitive investorsFirst dividend Apr 202120.0c annualised at FY26 (10.0c Oct 2026)
Dividend Reinvestment Plan (DRP)Shares acquired on-market since 2024 (no dilution)Long-term holdersOperational by FY2022Market-based DRP price
Weekly NTA and monthly investment updatesTransparency reporting to ASXAll shareholdersSince listingFree
Investor hub (investors.hm1.com.au)Q&A and comment platformShareholdersReferenced 2026Free
Sohn Hearts & Minds Investment Leaders Conference (affiliate)Annual stock-pitch and philanthropy event; source of Conference PortfolioInvestors, industry2,016Ticketed (pricing not disclosed in sources reviewed)
Hearts & Minds Podcast / insightsManager and researcher interviewsPublic~2024Free

Portfolio holdings — complete list at 30 June 2026 (the "product shelf")

HoldingExchangeFair value (AUD)% of portfolioSleeve / sponsor (where disclosed)
Taiwan Semiconductor (ADR)NYSE67,248,3157.9Core (named FY26 contributor)
ACM Research (Cl A)Nasdaq63,073,7097.4Conference 2025 — Beeneet Kothari, Tekne Capital (+283% since purchase)
NvidiaNasdaq41,923,3444.9Core
Block (Cl A)NYSE40,962,3584.8Not disclosed (held since at least FY2024)
Brookdale Senior LivingNYSE40,849,8374.8Conference 2025 — Vihari Ross, Antipodes
Amazon.comNasdaq36,402,7714.3Core
Rokt Pte LtdUnlisted36,247,0924.3Core (sole unlisted holding; carried at US$45/share)
Steel DynamicsNasdaq35,477,5234.2Conference 2025 — Peter Rutter, Life Cycle Investment Partners
Live Nation EntertainmentNYSE32,676,9533.9—
Royalty Pharma (Cl A)Nasdaq32,408,0633.8Core
CamecoTSX31,472,0383.7Core
SLBNYSE31,438,9423.7Conference 2025 — Robert Mullin, Marathon Resource Advisors
CK Hutchison (CKH Holdings)HKSE30,514,8853.6Core
AdidasXetra/DAX30,200,0933.6—
Swire Pacific (A)HKSE26,627,8283.1Originally 2023 conference pick; current sponsor not disclosed
Guzman y GomezASX26,287,5003.1Core (pre-IPO investment Jan 2023)
AIA GroupHKSE25,933,0923.1Originally 2023 conference pick; current sponsor not disclosed
MicrosoftNasdaq25,008,8613.0Core
CATL (H shares)HKSE23,539,3442.8—
Zillow Group (Cl C)Nasdaq22,772,9212.7Core
PuuiloHelsinki20,748,6592.4—
Monday.comNasdaq19,142,2152.3Conference 2025 (presenter not specified)
SAPXetra/DAX17,913,2952.1Core
Heidelberg MaterialsXetra/DAX15,700,6221.9—
BlackLineNasdaq13,587,8191.6Conference 2025 (presenter not specified)
DiDi Global (ADR)OTC Pink12,779,4231.5—
Morimatsu InternationalHKSE12,718,1441.5—
Corporate Travel ManagementASX (suspended at 30 Jun 2026)00.0Conference 2024 — Rikki Bannan, IFM Investors (1,251,663 shares)
Cash and equivalents—33,956,7744.0—
Total portfolio—847,612,422100.0—

Source: FY2026 Investment Committee Report; FNN (CTD sponsor). Analyst note: the step-up in Hong Kong exposure (HKD 1% at FY25 to 15% at FY26) coincides with Prusik's appointment as Asia ex-Japan Core manager in September 2025; holdings such as CATL and Morimatsu are plausibly Prusik ideas, but manager attribution is not disclosed.

Portfolio construction parameters

  • Holdings: FY2026 report cites 20–25 stocks typically; the website and FY2024/25 materials cite 25–35 (or 25–30). Discrepancy noted — the FY2026 annual report is the more recent primary source. Count at 30 June 2026: 27 securities with non-zero value plus CTD at zero.

  • Unhedged currency exposure (policy).

  • Fully invested subject to a cash buffer for tax, dividends, donations and expenses.

  • Unlisted exposure constrained (one holding, 4.3%).

Financial Narrative

Basis: Australian Accounting Standards / IFRS; A$; FY ends 30 June. Concepts such as gross profit, operating income and EBITDA have no standard LIC meaning; the closest analogues are presented and labelled.

Income statement

Sources: FY2024 and FY2026 Annual Reports (statements of comprehensive income; remuneration report five-year table). Margins and tax rate calculated. Gross profit, operating income and EBITDA as defined for trading companies: N/A (no cost of sales, no depreciation/amortisation, negligible interest expense — A$6 in FY2024, nil FY2026). Interest income was A$6,959 in FY2026.

Investment income CAGR (FY2023–FY2026): 11.2% p.a. (calculated). This figure is not economically meaningful given the volatility of mark-to-market income; NTA growth plus dividends is the appropriate measure.

Commentary. HM1's reported earnings track equity markets and manager selection. FY2022 was the inflection low: the growth- and technology-heavy portfolio built in 2020–21 fell sharply as rates rose, producing a A$219.6m comprehensive loss and cutting post-tax NTA from A$3.92 (FY2021) to A$2.81. The FY2023 rebuild (new CIO, new Core managers including Munro) drove a recovery through FY2024 and a record FY2025 (portfolio +25.5%, NPAT A$106.8m), powered by AI-linked holdings (Nvidia, TSMC), Guzman y Gomez's IPO and Rokt's revaluation. FY2026 earnings halved: a 5.2% pre-tax portfolio return was dragged by the "SaaSpocalypse" sell-off in application software (Zillow, SAP, Microsoft, Monday.com, BlackLine), Block and Guzman y Gomez weakness, AUD strength (unrealised FX loss of A$9.8m) and the write-off of CTD. Note that OCI (pre-October 2021 holdings) swung to a A$16.8m loss in FY2026 as legacy FVTOCI positions were realised at losses.

NTA, share price and per-share metrics

Sources: FY2024/FY2026 Annual Reports; FY2025 Annual Report summary (TSR 24%). FY2022 and FY2023 portfolio returns are derived from the FY2024 multi-period returns (2-year 13.4% p.a.; 3-year −5.1% p.a.) and are not directly reported figures. FY2023 TSR (18.1%) from InvestSMART (secondary). Discounts calculated; company reported FY2026 discount of 12.7% and FY2025 of 11.8% (minor rounding difference vs 11.6% calculated from A$3.04/A$3.44).

Balance sheet

Sources: FY2024 and FY2026 Statements of Financial Position and Changes in Equity; FY2022 cash from FY2023 cash-flow opening balance; FY2022 share capital and profits reserve from FY2024 Statement of Changes in Equity (1 July 2022 balances). Working capital calculated (current assets include FVTPL equities).

Commentary. HM1 is debt-free and has never used gearing. The balance sheet's main moving parts are the investment portfolio, the deferred tax liability on unrealised gains (which rose from A$5.9m to A$54.9m as the portfolio recovered, then eased to A$49.6m), and the current tax liability (A$15.9m at FY2026, reflecting heavy realised gains). Cash has been run down from A$122m (FY2022) to A$34m (FY2026, 4.0% of portfolio), consistent with the "fully invested" mandate. The profits reserve — the pool from which dividends are paid — jumped to A$201.1m (87.8c per share) after A$112.2m was transferred from retained earnings in FY2026.

Cash flow

Sources: FY2024 and FY2026 Statements of Cash Flows; Note 9(d). "Free cash flow" in the corporate sense is not meaningful for an LIC; dividends are funded by realising portfolio gains (investing cash flow).

Commentary. Portfolio turnover is high for a "high-conviction" vehicle: FY2026 sales of A$460.9m equate to ~59% of average portfolio value, reflecting the annual rotation of the 35% Conference sleeve plus Core changes. Rising tax paid (A$9.3m in FY2026 versus nil in prior years, after carried-forward losses were exhausted) replenishes the franking account and supports future franked dividends.

Ratios

Calculated from FY2024 and FY2026 Annual Reports. Net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle: N/A (no debt, no interest expense of significance, no inventory/receivables cycle). Payout is computed on cash dividends excluding DRP reinvestment.

Franking and dividend capacity

Source: FY2024 and FY2026 Note 3(f), Note 9. Analyst calculation: each 1.0c fully franked dividend (on 228.98m shares) consumes ≈A$0.98m of franking credits; A$33.2m available credits support ≈34c of fully franked dividends before new tax payments — about 1.7 years at the 20c annualised run-rate. Ongoing tax payments on realised gains are therefore essential to sustain the policy.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Sleeve Details

SleeveTarget weightCompositionHolding periodGovernance

Core Portfolio

~65%

Up to 20 securities; each Core Fund Manager supplies its three highest-conviction ideas, reviewed quarterly

Ongoing

CIO and Core Fund Managers monitor; Investment Committee oversees

Conference Portfolio

~35%

10–15 securities pitched at the annual Sohn Hearts & Minds Conference, generally equal-weighted

Up to ~12 months, then rotated into next conference's picks

Conference Fund Manager Selection Working Group selects speakers

Expense line (AUD Mn)

Expense line (AUD Mn)FY2023FY2024FY2025FY2026

Donations to medical research

10.0910.0911.2511.52

Employee costs

0.950.951.380.99

Other expenses (incl. interest)

0.880.650.771.18

Total expenses

11.9211.6913.4113.69

Donations as % of total expenses

84.686.383.984.1

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total investment income (AUD Mn) — "revenue"

—57.5883.37165.4879.32

Total expenses (AUD Mn)

—11.9211.6913.4113.69

Income before tax (AUD Mn) — EBIT/EBITDA proxy

—45.6671.68152.0865.63

Income tax expense (AUD Mn)

—12.9320.7545.2619.25

Net income after tax (AUD Mn)

—32.7350.93106.8246.37

Other comprehensive income, net of tax (AUD Mn)

—30.232.5317.97-16.82

Total comprehensive income (AUD Mn)

-219.5962.9553.45124.7829.55

Basic & diluted EPS (A cents)

—14.3522.2646.6520.25

Dividends paid during year (A cents per share)

13.513.514.015.518.5

Pre-tax margin (%)

—79.386.091.982.7

Net margin (%)

—56.861.164.558.5

Effective tax rate on P&L (%)

—28.328.929.829.3

Per-Share Data and Share Price

MetricFY2022FY2023FY2024FY2025FY2026

Pre-tax NTA per share (AUD)

—2.903.093.713.67

Post-tax NTA per share (AUD)

2.812.953.053.443.38

Share price at 30 June (AUD)

2.022.262.583.042.95

Share price / post-tax NTA (x)

0.720.770.850.880.87

Discount to post-tax NTA (%)

28.123.415.411.612.7

Portfolio pre-tax return after expenses (%)

-33.915.111.725.55.2

Total shareholder return (%)

—18.120.024.03.1

Shares on issue (millions)

227.85228.80228.98228.98228.98

Balance Sheet

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Total assets

—687.26730.51857.95848.00

Cash and cash equivalents

122.0359.2565.9236.0133.96

Financial assets at FVTPL

—479.95553.56767.64783.75

Financial assets at FVTOCI

—129.2394.0854.0729.90

Deferred tax assets

—17.979.740.000.00

Total liabilities

—11.7433.1071.2574.11

Deferred tax liabilities

—5.9119.5254.8949.64

Current tax liabilities

—0.000.007.8815.91

Donation provision

—5.736.448.168.29

Total borrowings (short + long term)

00000

Net debt (cash negative = net cash)

-122.03-59.25-65.92-36.01-33.96

Shareholders' equity

641.13675.52697.41786.70773.89

Share capital

572.28574.48574.94574.94574.94

Profits reserve

174.03153.27132.92146.57201.13

Goodwill & intangibles

00000

Working capital (current assets − current liabilities)

—534.24613.11787.52793.63

Cash Flow

Metric (AUD Mn)FY2023FY2024FY2025FY2026

Net operating cash flow

7.60-3.30-2.55-13.14

of which donations paid

-10.24-9.37-9.54-11.38

of which income tax (paid)/refunded

15.000.000.03-9.26

of which dividends received

4.667.648.629.69

Net investing cash flow (sales less purchases)

-43.8642.574.3257.27

Proceeds from sale of investments

444.41332.52412.18460.90

Purchases of investments

488.27289.96407.86403.63

Capex

0000

Free cash flow (operating − capex)

7.60-3.30-2.55-13.14

Dividends paid (cash)

28.5631.5735.4942.36

Dividends reinvested via DRP (non-cash)

3.773.522.132.23

Share buybacks

0000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE — net income / avg equity (%)

5.07.414.45.9

ROE — total comprehensive income / avg equity (%)

9.67.816.83.8

ROA — net income / avg total assets (%)

—7.213.45.4

ROIC (%) — equal to ROE (no debt)

5.07.414.45.9

Current ratio (x)

92.746.249.133.4

Debt / equity (x)

0000

Total expenses / avg equity (%)

1.811.701.811.75

Non-donation expenses / avg equity (%)

0.280.230.290.28

Dividend payout (cash dividends / net income, %)

87.362.033.291.4

Portfolio turnover (sales / avg investments, %)

—50.255.658.9

Dividends & Capital Returns

Metric (AUD Mn)FY2023FY2024FY2025FY2026

Franking account closing balance

54.4041.2926.0617.27

Franking credits available for subsequent periods

54.4241.2933.9533.17

Franking credits used on dividends paid

13.1813.7315.2118.16

Profits reserve

153.27132.92146.57201.13

Revenue by Region (%)

Currency exposure (% of portfolio)FY2023FY2024FY2025FY2026

United States Dollar

56597068

Hong Kong Dollar

17115

Euro

103810

Canadian Dollar

3654

Pound Sterling

2720

Australian Dollar (residual, calculated)

2818143

Venue Details

VenueWeight (%)Holdings

Nasdaq (US)

34.2

ACM Research, Nvidia, Amazon, Steel Dynamics, Royalty Pharma, Microsoft, Zillow, Monday.com, BlackLine

NYSE (US)

25.1

TSMC ADR, Block, Brookdale, Live Nation, SLB

Hong Kong (HKSE)

14.1

CK Hutchison, Swire Pacific, AIA, CATL, Morimatsu

Germany (Xetra)

7.6

Adidas, SAP, Heidelberg Materials

Unlisted (Singapore-domiciled Rokt)

4.3

Rokt

Cash

4.0—

Canada (TSX)

3.7

Cameco

Australia (ASX)

3.1

Guzman y Gomez (CTD at zero)

Finland (Helsinki)

2.4

Puuilo

US OTC

1.5

DiDi Global

Share Price History

PeriodStart price (AUD)End price (AUD)Change (%)Basis

1-year (30 Jun 2025 → 30 Jun 2026)

3.042.95-3.0

FY AR prices

3-year (30 Jun 2023 → 30 Jun 2026)

2.262.9530.5

FY AR prices

5-year (30 Jun 2021 → 30 Jun 2026)

4.322.95-31.7

FY24/FY26 AR tables

Since IPO (Nov 2018 → 30 Jun 2026)

2.502.9518.0

FY26 AR

Calendar 2026 YTD (to 11 Sep 2026)

3.182.87-9.8

InvestSMART (secondary)

52-week range (to Sep 2026)

2.653.51—

SmallCaps (secondary)

Share price at 30 June (AUD)

Share price at 30 June (AUD)FY2022FY2023FY2024FY2025FY2026

HM1 share price

2.022.262.583.042.95

Post-tax NTA per share

2.812.953.053.443.38

Valuation Multiples

MultipleHM1Basis

P/E (trailing FY2026 EPS 20.25c)

14.2x

Calculated

P/E (FY2025 EPS 46.65c)

6.2x

Calculated

Price / post-tax NTA (A$3.38, 30 Jun 2026)

0.85x

Calculated

Price / pre-tax NTA (A$3.67)

0.78x

Calculated

EV (market cap A$657m − cash A$34m)

≈A$623m

Calculated

EV/EBITDA, EV/Sales

Not meaningful for an LIC

—

Dividends paid (A cents per share)

Dividends paid (A cents per share)FY2021FY2022FY2023FY2024FY2025FY2026

Fully franked dividends paid in year

12.013.513.514.015.518.5

Payment date

Amount (c)

Type

Franking

———

20 Apr 2021

12.0

Annual

100%———

12 Apr 2022

13.5

Annual

100%———

13 Apr 2023

13.5

Annual

100%———

19 Oct 2023

7.0 (derived)

Half-yearly

100%———

18 Apr 2024

7.0 (derived)

Half-yearly

100%———

17 Oct 2024

7.5

Final

100%———

17 Apr 2025

8.0

Interim

100%———

16 Oct 2025

9.0

Final

100%———

16 Apr 2026

9.5

Interim

100%———

15 Oct 2026

10.0

Final (declared)

100%———

Analyst Conclusions

Management guidance

No financial guidance is provided. The Board commits to (i) continuing fully franked dividends with half-yearly 0.5c increments, (ii) the 1.5% NTA donation, (iii) narrowing the discount to NTA, and (iv) enhancing risk management via Plato's screen. The Directors note performance depends on investee and macro factors and cannot be predicted.

Consensus expectations

No analyst consensus exists. Mechanically, the dividend policy implies 10.5c (Apr 2027) and 11.0c (Oct 2027), i.e., ≈21.5c over the next 12 months versus 20.0c annualised today.

Bull case

  1. Discount re-rating: at 0.85x post-tax NTA, closing half the 12.7% discount alone would deliver ~6–7% upside before portfolio returns, and the Board has publicly committed to narrowing it.

  2. Recoveries and catalysts embedded in NTA: CTD's return to trading (carried at zero at FY2026) and a potential Rokt liquidity event (A$36.2m, held flat at US$45) offer asymmetric NTA upside.

  3. Yield support: 7.0% cash yield (≈10% grossed-up) backed by A$201m profits reserve and A$33m franking credits, plus rising tax payments replenishing franking.

Bear case

  1. Persistent alpha deficit: underperformance versus MSCI World in FY2024 and HY2026 undermines the active proposition when ETFs cost a fraction of HM1's ~1.75% all-in expense ratio (including donations).

  2. Process risk: two write-to-zero events reported in 2025 and high portfolio turnover (~59%) suggest uneven idea quality; the Plato overlay is untested.

  3. Governance/structure: related-party donation concentration (43% to one director-linked institute), leadership churn, and a retail register that limits activist pressure could keep the discount entrenched.

Key catalysts and monitorables (next 12 months)

Date / timingCatalystWhat to watch
15 Oct 202610.0c dividend paymentDRP participation
6 Nov 2026Queenstown Sohn Hearts & Minds ConferenceQuality and sector mix of 10–15 new picks
19 Nov 2026AGMDiscount-management measures (buyback?), Plato rollout detail, board renewal/diversity
Ongoing (weekly)NTA estimatesCTD valuation post-relisting; FX moves
Q4 2026–2027RoktAny IPO, funding round or revaluation
Feb 2027HY2027 resultsInterim dividend 10.5c per policy; performance vs MSCI World
2,027Core manager panelFurther changes after Prusik; manager attribution transparency
2,027Franking balanceTax paid vs dividend franking usage

Analyst verdict

Hearts and Minds Investments is a genuinely differentiated vehicle: a debt-free, fee-free (to managers) global equity portfolio whose cost structure is redirected to Australian medical research, governed by an unusually experienced and unpaid board. Its financial position is robust — A$774 million of net assets, no borrowings, a profits reserve of roughly 88 cents per share and enough franking to support the progressive dividend for well over a year even without fresh tax payments. Over three years to June 2026 the portfolio compounded at 13.8% per annum, and the dividend has risen from 13.5 cents to a 20-cent annual run-rate.

The difficulty is that investors have not been rewarded commensurately. The shares have traded below post-tax NTA continuously since the FY2022 drawdown, and the most recent period exposed process weaknesses: a flat first half of FY2026 against a 9% market gain, a high-profile write-off of Corporate Travel Management, and exposure to both sides of the AI trade. Leadership churn in 2024–25 and the concentration of donations in a director-linked institute are governance points that a premium-rating LIC would typically have resolved.

On balance, HM1 screens as a value-and-income proposition rather than a growth story: at about 0.85 times post-tax NTA with a 7% fully franked yield, the price already discounts mediocre stock selection, while CTD's relisting, a possible Rokt event and the Plato risk overlay offer upside optionality. The decisive variables are execution of the new risk framework, the quality of the Queenstown conference picks, and whether the Board backs its stated commitment to narrowing the discount with concrete capital management. Absent such action, the discount is likely to persist, and returns will track a volatile, concentrated portfolio plus the dividend. Investors who value the philanthropic dimension may reasonably accept that trade-off; purely return-focused investors should demand evidence of sustained benchmark outperformance first.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationFY2026 total remuneration (AUD)

Richard Howes

Managing Director (part-time) and Director

Since 1 Jun 2025

Group CEO & MD, Challenger Limited; 19 years at Challenger incl. CIO and CEO of annuity business; Zurich Capital Markets, Macquarie, Bankers Trust; QIC strategy

B.Com (Hons) and Economics, University of Queensland; Harvard AMP

237,500 (fees under services agreement; no super, no equity, no incentive)

Charlie Lanchester

Chief Investment Officer

Since 12 Apr 2023

Head of Fundamental Australian Active Equities, BlackRock; Perpetual, Platinum, Schroders

—

250,500 (A$225,000 fixed + A$25,500 superannuation)

Natalie Climo

Company Secretary (Boardroom employee)

Appointed after Feb 2024 (exact date not disclosed in sources reviewed)

Governance professional and lawyer

——

“—” = not publicly disclosed.

Directors' Remuneration

KMP remuneration (AUD)FY2022FY2023FY2024FY2025FY2026

Total KMP remuneration

501,000781,871609,8911,092,353488,000

Board of Directors

DirectorRoleAppointedBackgroundOther notable rolesHM1 shares (30 Jun 2026)

Christopher Cuffe AO

Chair, Independent

12 Sep 2018

CEO Colonial First State (1990–2003); CEO Challenger Group (2003); chartered accountant

Director, Staude Capital Global Value Fund; Third Link Growth Fund founder/PM

150,000

Lorraine Berends AM

Independent; Chair, Investment Committee

—

15 years at Marvin & Palmer; former Chair of CIMA Society and ASFA; FIAA

NED Pinnacle Investment Management, Plato Income Maximiser, Spheria Emerging Companies

45,000

Guy Fowler OAM

Independent; co-founder

Oct 2018

25+ years UBS (Head of Capital Markets, Corporate Advisory); founder & Co-Executive Chair Barrenjoey

—1,426,211

Matthew Grounds AM

Independent; co-founder; IC member

—

UBS ANZ CEO for 11 years; Joint Global Head of IB; Co-Executive Chair Barrenjoey

Chairman, Victor Chang Cardiac Research Institute

1,260,959

Michael Traill AM

Independent

—

Founding CEO Social Ventures Australia; co-founder Macquarie Direct Investment

Executive Chair For Purpose Investments; Chair of Paul Ramsay Foundation until 30 Jun 2026

72,281

Gary Weiss AM

Independent; co-founder

—

Former Chair Coats PLC, Estia Health, ClearView; ex-Guinness Peat

Exec Director Ariadne; Chair Coast Entertainment, Cromwell; Interim Chair Webjet (May 2026); Deputy Chair Myer; NED Straits Trading (Apr 2026), Thorney Opportunities, Victor Chang Institute

507,846

Geoffrey Wilson AO

Independent

—

Founder Wilson Asset Management (A$6bn+, 130,000 investors)

Chair of eight WAM LICs; founder/director Future Generation Australia, Global and Women

1,687,500

David Wright

Independent; IC member

—

Co-founder and former CEO Zenith Investment Partners

Head of Client Solutions, Pinnacle Investment Management

106,239

Richard Howes

Managing Director

1 Jun 2025

See 9.1

UTS Council; Edge Zero board

105,000

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

1 Feb 2023

CIO Rory Lucas departs

Portfolio management overhaul

12 Apr 2023

Charlie Lanchester appointed CIO

Ex-BlackRock

21 Feb 2024

Company Secretary Tom Bloomfield resigns; Eryl Baron appointed

Boardroom personnel change

5 Dec 2024

CEO Paul Rayson announces retirement (effective 19 Feb 2025); Brett Jollie appointed

Founding CEO since 2018

19 May 2025

Jollie to step down 30 Jun 2025 after ~6 months; part-time MD model adopted

Board cited Jollie's operating-model review and portfolio-management automation as enabling a leaner structure; no departure reason given

1 Jun 2025

Richard Howes appointed MD and director

Former Challenger CEO

By Aug 2026

Natalie Climo is Company Secretary

Boardroom employee

Governance Detail

Victor Chang Cardiac Research Institute donationsFY2023FY2024FY2025FY2026

Donation to Victor Chang Institute (AUD Mn)

5.044.144.504.96

Share of total donations expense (%)

49.941.040.043.1

Competitive Landscape

Key Competitors

CompetitorTickerCategoryRelative positioning vs HM1

Future Generation Global Investment Company

FGG

Philanthropic global LIC (pro bono managers, 1% of NTA donated)

Most direct model peer; founded by HM1 director Geoff Wilson; fund-of-managers rather than direct stock picks

Future Generation Australia

FGX

Philanthropic Australian-equity LIC

Same philanthropic model, domestic focus

WAM Global

WGB

Global LIC (Wilson Asset Management)

Fee-charging; mid-cap global focus; Wilson-linked

MFF Capital Investments

MFF

Concentrated global LIC

Larger, concentrated quality portfolio; strong long-term record

Magellan Global Fund (closed class)

MGF

Global listed fund

Magellan is also an HM1 Core manager

Platinum Capital

PMC

Global LIC

Value/contrarian; style contrast

Pengana International Equities

PIA

Global LIC

Fee-charging global ethical/quality

Regal Investment Fund

RF1

Alternatives listed trust

Regal was formerly an HM1 Core manager

L1 Long Short Fund

LSF

Long/short listed fund

Competes for HNW active allocations

Global equity ETFs (e.g., Vanguard, iShares MSCI World products)

VGS, IVV, IOO

Passive

Ultra-low fees; HM1's FY24 and HY26 underperformance vs MSCI World strengthens passive alternative

Peer Comparison FY2026

MetricHM1MSCI World (AUD)Notes

FY2024 return (%)

11.718.3

FY24 AR

2-year return to FY2024 (% p.a.)

13.419.5

FY24 AR

3-year return to FY2024 (% p.a.)

-5.19.3

FY24 AR

Since inception to FY2024 (% p.a.)

9.311.8

FY24 AR

HY2026 return (%)

0.4

9.2 (Accumulation)

HY26 announcement (secondary)

Since inception to FY2026 (% p.a.)

10.7

Not disclosed in FY26 AR

FY26 AR dropped benchmark comparison

Recent Developments

--

Company Snapshot

4

Employees

2018

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Zero fee drag to managers: A$12.42m of fees forgone in FY2026 (FY26 AR Note 2(k)).
  • Debt-free balance sheet: nil borrowings across FY2022–FY2026; net cash A$34.0m at FY2026.
  • Dividend capacity: profits reserve A$201.1m (≈88c/share) at 30 June 2026 versus 20c annualised dividend (FY26 AR Note 9).
  • Lean cost base: non-donation expenses A$2.17m in FY2026 (≈0.28% of average equity); KMP remuneration cut to A$488k from A$1.09m.
  • Long-run returns: 10.7% p.a. pre-tax since inception and 13.8% p.a. over three years to FY2026 (FY26 AR).
  • Philanthropic franchise: A$96.1m cumulative donations with the conference; 21 research beneficiaries (FY26 AR).

Weaknesses

  • Persistent discount: 12.7% to post-tax NTA at FY2026 (≈20% to pre-tax), and 28% at FY2022.
  • Benchmark lag: FY2024 return 11.7% vs MSCI World 18.3%; HY2026 0.4% vs 9.2%.
  • Stock-specific blow-ups: CTD written to zero (~A$20m position at cost) after only months; FNN reported another write-to-zero earlier in 2025.
  • Leadership churn: three CEO/MD changes between Dec 2024 and Jun 2025.
  • Related-party donation concentration: 43% of FY2026 donations went to the Victor Chang Institute, chaired by a HM1 director.
  • Low board gender diversity: 1 of 9 directors female.

Opportunities

  • Rokt liquidity event: carried at US$45/share (A$36.2m); an IPO or sale above carrying value would crystallise gains.
  • Process upgrade: Plato's 150-category red-flag screen could reduce left-tail outcomes.
  • Asian diversification: Prusik's appointment broadens opportunity set into undervalued Asian equities (HKD exposure 15%).
  • Conference internationalisation: Queenstown 2026 may attract new speakers, sponsors and investors.
  • Discount-narrowing tools: the Board has stated commitment; buybacks have not been used and remain an option given A$201m reserves.

Threats

  • Passive competition: low-cost MSCI World ETFs outperformed HM1 in FY2024 and HY2026.
  • Currency: unhedged; a 10% AUD rise reduces profit by ~A$38.2m on USD alone (FY26 Note 13).
  • Equity drawdown: a 20% market fall would reduce profit by ~A$109.7m after tax (FY26 Note 13).
  • Tech/AI concentration: TSMC, Nvidia and ACM Research alone were 20.2% of the portfolio at FY2026.
  • Franking depletion: available credits A$33.2m support ~34c of dividends without fresh tax payments.
  • Key-relationship risk: model depends on continuing pro bono participation by managers, directors and service providers.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17 Apr 2025Interim dividend 8.0c fully franked paid; 713,180 DRP shares bought on-marketDividend growth continues
19 May 2025Leadership restructure: CEO Brett Jollie to depart 30 Jun 2025; part-time MD modelGovernance turbulence (third CEO-level change in six months) but lower cost
1 Jun 2025Richard Howes joins as MD and directorSeasoned listed-company CEO
30 Jun 2025FY2025 close: portfolio +25.5%; post-tax NTA A$3.44; price A$3.04Record year
Aug 2025August portfolio −0.05% vs MSCI World +0.85%Since-inception return 12.05% p.a. at that date
22 Aug 2025CTD suspended from ASX pending audit issuesSingle-stock governance risk materialises
28 Aug 2025FY2025 Annual Report: NII A$165.5m (+98%), NPAT A$106.8m (+110%); final 9.0c declared; +0.5c/half policyRecord profit; dividend policy formalised
1 Sep 2025Prusik appointed Core Fund ManagerFirst offshore core manager; Asia tilt
16 Oct 2025Final 9.0c dividend paid; 612,652 DRP shares bought on-market—
Nov 2025Tenth Sohn Hearts & Minds Conference at Sydney Opera House; 2025 picks include ACM Research, Brookdale, Steel Dynamics, SLB, Monday.com, BlackLineNew Conference sleeve
Nov 2025CTD fair-valued at zero; November portfolio −5.7%FNN reported it as the second write-to-zero in 2025 (first position not identified in primary sources reviewed; unconfirmed)
26 Nov 2025AGM held—
28 Nov 2025CTD discloses ~GBP77.6m revenue overstatement across FY23–FY25 and ~A$162m customer refundsConfirms severity of CTD issue
10 Dec 2025November investment update—
13–14 Jan 2026December investment update and revised updateReporting correction issued
Jan–Feb 2026Sharp software sell-off ("SaaSpocalypse") hits Zillow, SAP, Microsoft, Monday.com, BlackLineMajor FY26 detractor
18 Feb 2026HY2026: TCI A$3.0m (vs A$115.3m pcp); portfolio +0.4% vs MSCI World +9.2%; interim 9.5c; profits reserve 86c/shareSignificant benchmark underperformance
25 Feb 2026Ex-dividend date for 9.5c interim—
Mar 2026Weekly NTA volatility; share price trades A$2.71–2.98Discount persists
8 Apr 2026Dividend/distribution update (DRP price)—
16 Apr 2026Interim 9.5c paid; 809,633 DRP shares bought on-market—
Apr–May 2026Director Gary Weiss joins Straits Trading board (Apr) and becomes Interim Chair of Webjet (May)Director workload consideration
8–13 May 2026Manager interview (SLB pick); "10 Years of Hearts & Minds" campaignBrand/marketing
30 Jun 2026FY2026 close: portfolio +5.2%; post-tax NTA A$3.38; price A$2.95; Michael Traill ends Paul Ramsay Foundation chair roleSubdued year
Jul 2026July portfolio −2%; reports CTD in repayment talks with UK government (~GBP128m) and facing delisting deadlineCTD recovery uncertain
13 Aug 2026July investment update—
26 Aug 2026FY2026 results: NPAT A$46.4m (−57%); final 10.0c; Plato risk overlay; Queenstown conferenceProcess upgrade response to CTD
Early Sep 2026CTD recommences ASX trading; HM1 values holding at market–
9–15 Sep 2026Ex-dividend 9 Sep; record 10 Sep; share price falls to A$2.84–2.87—
23 Sep 2026Director nomination deadline for AGM—
15 Oct 2026 (upcoming)Final 10.0c dividend payment—
6 Nov 2026 (upcoming)Queenstown conference — new Conference sleeve picksKey catalyst
19 Nov 2026 (upcoming)AGMGovernance and discount questions likely

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Region (%): United States Dollar rose from 56% in FY2023 to 68% in FY2026.
Hearts and Minds Investments Limited — Revenue by Region (%)
Series (%)FY2023FY2024FY2025FY2026
United States Dollar56597068
Hong Kong Dollar17115
Euro103810
Canadian Dollar3654
Pound Sterling2720
Australian Dollar (residual, calculated)2818143

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.